Literature DB >> 15533476

Management of renal masses in patients medically unsuitable for nephrectomy--natural history, complications, and outcome.

Gavin W A Lamb1, Emma J Bromwich, Paul Vasey, Michael Aitchison.   

Abstract

OBJECTIVES: To examine a group of elderly patients with much larger tumors who were deemed unlikely to survive surgery or who would require dialysis postoperatively to establish the natural history of larger renal tumors if left untreated. Little is known of the growth rate and natural history of renal cancer progression because the tumor is usually removed in those patients who can tolerate surgery. The only published data have been in relation to unfit patients with small, homogeneous, well-circumscribed tumors less than 4 cm.
METHODS: We identified 36 patients whose tumor had not been removed, without evidence of metastasis at diagnosis, from a database of 421 patients with renal cancer. The data were examined retrospectively for symptoms, survival, and size change.
RESULTS: The mean age of the patients treated conservatively was 76.1 years (range 56 to 91), with median tumor size of 6.0 cm (range 3.5 to 20.0) at diagnosis. The median follow-up period was 24 months (range 3 to 136). Of the 36 patients, 13 had died at follow-up, 8 of an unrelated illness and 5 of an unknown cause with no radiologic evidence of progression but severe comorbidity. The median time to death was 9 months (range 3 to 24) after diagnosis. One patient developed metastasis at 132 months and was still alive at 136 months of follow-up. Significant hematuria occurred in 11% of the patients and was successfully managed either conservatively or by embolization. The tumor size was unchanged in most patients during the follow-up period.
CONCLUSIONS: In elderly patients, or those with severe comorbidity, conservative management of larger renal masses is a reasonable and safe option.

Entities:  

Mesh:

Year:  2004        PMID: 15533476     DOI: 10.1016/j.urology.2004.05.039

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  28 in total

1.  Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis.

Authors:  Pari V Pandharipande; Debra A Gervais; Rebecca I Hartman; Mukesh G Harisinghani; Adam S Feldman; Peter R Mueller; G Scott Gazelle
Journal:  Radiology       Date:  2010-09       Impact factor: 11.105

2.  Optimal follow-up intervals in active surveillance of renal masses in patients with von Hippel-Lindau disease.

Authors:  Fabio Pomerri; Giuseppe Opocher; Chiara Dal Bosco; Pier Carlo Muzzio; Gisella Gennaro
Journal:  Eur Radiol       Date:  2015-01-31       Impact factor: 5.315

3.  Active surveillance for small renal masses.

Authors:  Phillip M Pierorazio; Elias S Hyams; Jeffrey K Mullins; Mohamad E Allaf
Journal:  Rev Urol       Date:  2012

Review 4.  Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis.

Authors:  Marc C Smaldone; Alexander Kutikov; Brian L Egleston; Daniel J Canter; Rosalia Viterbo; David Y T Chen; Michael A Jewett; Richard E Greenberg; Robert G Uzzo
Journal:  Cancer       Date:  2011-07-15       Impact factor: 6.860

5.  Growth pattern of renal cell carcinoma (RCC) in patients with delayed surgical intervention.

Authors:  Xue-Song Li; Lin Yao; Kan Gong; Wei Yu; Qun He; Li-Qun Zhou; Zhi-Song He
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

6.  Growth rates and outcomes of observed large renal masses.

Authors:  Naji J Touma; Gregory W Hosier; Michael A Di Lena; Robert J Leslie; Louisa Ho; Alexandre Menard; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2018-12-03       Impact factor: 1.862

7.  Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.

Authors:  Alexander Kutikov; Brian L Egleston; Yu-Ning Wong; Robert G Uzzo
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

8.  Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance.

Authors:  Paul L Crispen; Rosalia Viterbo; Stephen A Boorjian; Richard E Greenberg; David Y T Chen; Robert G Uzzo
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

9.  Progression to metastatic disease from a small renal cell carcinoma prospectively followed with an active surveillance protocol.

Authors:  Jaime A Wong; Ricardo A Rendon
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

10.  Watchful waiting in the treatment of the small renal mass.

Authors:  K Clint Cary; Chandru P Sundaram
Journal:  Indian J Urol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.